Stock Scorecard
Stock Summary for UroGen Pharma Ltd (URGN) - $17.07 as of 10/3/2025 3:32:25 PM EST
Total Score
8 out of 30
Safety Score
38 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for URGN
Positive Quarterly and Annual earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the Annual earnings growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for URGN
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for URGN
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for URGN
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for URGN (38 out of 100)
Stock Price Rating (Max of 10) | 6 |
Historical Stock Price Rating (Max of 10) | 4 |
Stock Price Trend (Max of 10) | 9 |
Book Value (Max of 10) | 1 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 5 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 9 |
Price to Earnings (Max of 10) | 0 |
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for URGN
Financial Details for URGN
Company Overview |
|
---|---|
Ticker | URGN |
Company Name | UroGen Pharma Ltd |
Country | USA |
Description | N/A |
Sector Name | HEALTHCARE |
Industry Name | BIOTECHNOLOGY |
Most Recent Quarter | 6/30/2025 |
Next Earnings Date | 11/17/2025 |
Stock Price History |
|
Last Day Price | 17.07 |
Price 4 Years Ago | 9.51 |
Last Day Price Updated | 10/3/2025 3:32:25 PM EST |
Last Day Volume | 1,014,934 |
Average Daily Volume | 1,211,019 |
52-Week High | 21.71 |
52-Week Low | 3.42 |
Last Price to 52 Week Low | 399.12% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 21.94 |
Sector PE | 41.81 |
5-Year Average PE | -4.24 |
Free Cash Flow Ratio | 8.49 |
Industry Free Cash Flow Ratio | 14.52 |
Sector Free Cash Flow Ratio | 30.43 |
Current Ratio Most Recent Quarter | 4.14 |
Total Cash Per Share | 2.01 |
Book Value Per Share Most Recent Quarter | -2.02 |
Price to Book Ratio | 19.27 |
Industry Price to Book Ratio | 29.60 |
Sector Price to Book Ratio | 32.30 |
Price to Sales Ratio Twelve Trailing Months | 8.54 |
Industry Price to Sales Ratio Twelve Trailing Months | 43.64 |
Sector Price to Sales Ratio Twelve Trailing Months | 20.26 |
Analyst Buy Ratings | 5 |
Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
Total Shares Outstanding | 46,264,100 |
Market Capitalization | 789,728,187 |
Institutional Ownership | 97.75% |
Dividends |
|
Ex-Dividend Date | N/A |
Previous Dividend Amount | 0.0000 |
Current Dividend Amount | 0.0000 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -24.09% |
Reported EPS 12 Trailing Months | -3.06 |
Reported EPS Past Year | -1.97 |
Reported EPS Prior Year | -3.23 |
Net Income Twelve Trailing Months | -154,968,000 |
Net Income Past Year | -126,874,000 |
Net Income Prior Year | -102,244,000 |
Quarterly Revenue Growth YOY | 10.80% |
5-Year Revenue Growth | 449.77% |
Operating Margin Twelve Trailing Months | -171.20% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 92,904,000 |
Total Cash Past Year | 171,987,000 |
Total Cash Prior Year | 95,002,000 |
Net Cash Position Most Recent Quarter | -29,204,000 |
Net Cash Position Past Year | 50,253,000 |
Long Term Debt Past Year | 121,734,000 |
Long Term Debt Prior Year | 98,551,000 |
Total Debt Most Recent Quarter | 122,108,000 |
Equity to Debt Ratio Past Year | -0.08 |
Equity to Debt Ratio Most Recent Quarter | -3.25 |
Total Stockholder Equity Past Year | -8,803,000 |
Total Stockholder Equity Prior Year | -65,212,000 |
Total Stockholder Equity Most Recent Quarter | -93,376,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -123,528,000 |
Free Cash Flow Per Share Twelve Trailing Months | -2.67 |
Free Cash Flow Past Year | -97,061,000 |
Free Cash Flow Prior Year | -76,570,000 |
Options |
|
Put/Call Ratio | 0.04 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.00 |
MACD Signal | 0.00 |
20-Day Bollinger Lower Band | 0.00 |
20-Day Bollinger Middle Band | 0.00 |
20-Day Bollinger Upper Band | 0.00 |
Beta | 1.02 |
RSI | 0.00 |
50-Day SMA | 0.00 |
150-Day SMA | 0.00 |
200-Day SMA | 0.00 |
System |
|
Modified | 10/4/2025 11:35:15 AM EST |